Ranitidine is an H2 (histamine-2) blocker, which decreases the amount of acid created by the stomach.
Apotex Inc. has begun shipments of Ranitaidine tablets to U.S. customer. Ranitidine is the generic equivalent to Glaxo's Zantac brand, an anti-ulcer drug.
In April of 2020 the FDA called for the removal of prescription and over the counter ranitidine products. The decision followed an investigation into the potential contamination of ranitidine products, from the known carcinogen N-nitrosodimethylamine (NDMA). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of the market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S